Isolating CD4+ and CD8+ T cells for improved drug efficacy and increased productivity
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Isolating CD4+ and CD8+ T cell subsets is critical for controlling the ratio within the final drug product. It also has impacts downstream steps such as cryopreservation after isolation. Achieving younger, less differentiated T cells is important for optimizing clinical outcomes. With this in mind, Thermo Fisher Scientific is releasing a first-of-its-kind platform technology that enables isolation of CD4+ and CD8+ T cells with a key differentiator: an active release mechanism for clinical trial or commercial manufacturing.
The Gibco™ CTS™ Detachable Dynabeads™ CD4 Kit and the Gibco™ CTS™ Detachable Dynabeads™ CD8 Kit each possesses a proprietary active release mechanism that enables active release of Dynabeads from the cells at any time in the process while maintaining high cell yield. Conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation markers, the performance exhibits consistent and optimal isolation and purity of target T cell populations while addressing the biological variability that cell therapy manufacturers are facing.
- How the active detachment of Dynabeads from target cells at any time allows users to add flexibility and scalability to their process
- How to maintain desired cell phenotypes
- How to isolate target cells for both autologous and allogeneic processes
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products
Precision in production: optimizing monitoring and quality control for high-value plasmids
Advancing cell therapy: innovations in polymer-based encapsulation and delivery
